2025 Oncology Institute
April 25, 2025 | 4:09 AM EST
- Home
- Clinical Resources Search
- PQI: Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma
Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma
About this PQI
The purpose of this PQI is to discuss the clinical considerations around the use of loncastuximab tesirine-lpyl (Zynlonta®) to optimize the outcomes for patients with relapsed/refractory large B-cell lymphoma.

How to Use a Positive Quality Intervention (PQI)
Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.
Find a PQIFind Similar Resources
All Resources
PQI
PQI
PQI
PQI
PQI: Epcoritamab (epcoritamab-bysp) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Author: Syed Zia Khan, PharmD, BCSCP
Last Updated: 04/25/2025
PQI: Ibrutinib Dosing Optimization
Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD
Last Updated: 04/25/2025
PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management
Author: Kayla Randle, PharmD, BCOP
Last Updated: 04/25/2025
PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Author: Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, FAPO
Last Updated: 04/25/2025
PQI in Action
PQI in Action
PQI in Action
PQI in Action
PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management
Author: Scripps Health, CA | UPMC, PA
Last Updated: 04/25/2025
PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations
Author: Florida Cancer Specialists & Research Institute, FL | Mayo Clinic, MN | Texas Oncology, TX
Last Updated: 04/25/2025
PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease
Author: University of Michigan Health-Sparrow Herbert-Herman Cancer Center, MI | Texas Oncology, TX | University of North Carolina (UNC) Health, NC
Last Updated: 04/25/2025
PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma
Author: Texas Oncology, TX | Florida Cancer Specialists & Research Institute, FL | University Hospitals Cleveland Medical Center, OH
Last Updated: 04/25/2025
PQI Podcast
PQI Podcast
PQI Podcast
PQI Podcast
The PQI Podcast S8 Ep 11: Honoring Her Legacy: A Conversation with Miss America 2024
Author: Ginger Blackmon, PharmD | Madison Marsh
Last Updated: 04/25/2025
The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting
Author: Ginger Blackmon, PharmD | Nick Bouchard, PharmD
Last Updated: 04/25/2025
The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program
Author: Ginger Blackmon, PharmD | Salvatore Bottiglieri, PharmD, BCOP
Last Updated: 04/25/2025
The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings
Author: Ginger Blackmon, PharmD | Shana O. Ntiri, MD, MPH, FAAFP,
Last Updated: 04/25/2025
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit
Treatment Support Kit: Abemaciclib
Last Updated: 04/25/2025
Treatment Support Kit: Temozolomide
Last Updated: 04/25/2025
Treatment Support Kit: Tivozanib
Last Updated: 04/25/2025
Treatment Support Kit: Regorafenib
Last Updated: 04/25/2025
Video
Video
Video
Video
Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide
Last Updated: 04/25/2025
Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Author: Brad Kahl, MD
Last Updated: 04/25/2025
Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications
Author: Jo Ellen Rodgers, PharmD, BCPS, BCCP
Last Updated: 04/25/2025
Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)
Author: Joyce O’Shaughnessy, MD
Last Updated: 04/25/2025
PQI
PQI
PQI
PQI
PQI: Epcoritamab (epcoritamab-bysp) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Author: Syed Zia Khan, PharmD, BCSCP
Last Updated: 04/25/2025
PQI: Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Author: Jeff Engle, PharmD, MS
Last Updated: 04/25/2025
PQI: Selinexor (Xpovio®) Patient Management
Author: Jeremiah Moore, PharmD
Last Updated: 04/25/2025
PQI: Glofitamab-gxbm (COLUMVI®) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Author: Matthew Lei, PharmD, BCOP | J. Erika Haydu, MD, PhD
Last Updated: 04/25/2025
PQI Podcast
PQI
PQI in Action
PQI Podcast
The PQI Podcast S8 Ep 11: Honoring Her Legacy: A Conversation with Miss America 2024
Author: Ginger Blackmon, PharmD | Madison Marsh
Last Updated: 04/25/2025
PQI: Epcoritamab (epcoritamab-bysp) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Author: Syed Zia Khan, PharmD, BCSCP
Last Updated: 04/25/2025
PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management
Author: Scripps Health, CA | UPMC, PA
Last Updated: 04/25/2025
The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting
Author: Ginger Blackmon, PharmD | Nick Bouchard, PharmD
Last Updated: 04/25/2025